A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

Inclusion Criteria: * Male participants: will be sterile (including vasectomy) or agree to use an effective method of birth control and will not donate sperm during the study and for 3 months following the last dose of the investigational product * Female participants: women not of childbearing potential Exclusion Criteria: * Have a history of or current, significant ophthalmic disease, as determined by the investigator or ophthalmologist * Have vitiligo or any other clinically significant disorder of skin pigmentation as determined by the investigator or dermatologist * Have a history or presence of significant bleeding disorders * Have a history of gastrointestinal ulcers with hemorrhage * Have a personal or family history of coagulation or bleeding disorders or reasonable suspicion of vascular malformations * Self-reported history of increased bleeding from trauma * Have a history of major head trauma (with loss of consciousness) within the past year or minor head trauma (without loss of consciousness) within the last 3 months prior to screening * History of major surgery within 3 months of screening * Planned surgery within 14 days after the last day of dosing * International Normalized Ratio (INR)/ Prothrombin Time (PT) or activated partial thromboplastin time above the normal reference range at screening * Abnormal Protein S antigen and/or Protein C activity as determined by the investigator * History of deep vein thrombosis and/or pulmonary embolism